Pfizer Healthcare Ireland - Результати пошуку

Європейський Союз - португальська - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agentes antineoplásicos - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Європейський Союз - португальська - EMA (European Medicines Agency)

vfend

pfizer europe ma eeig - voriconazol - candidiasis; mycoses; aspergillosis - antimicóticos para uso sistêmico - voriconazol, é um amplo espectro, triazole agente antifúngico e é indicado em adultos e crianças de 2 anos de idade e acima, como segue:o tratamento de aspergilose invasiva;tratamento de candidaemianon-neutropénicos de pacientes;tratamento de fluconazol resistente a sério invasivas de infecções por candida (incluindo c. krusei);tratamento de graves infecções fúngicas causadas por scedosporium spp. e fusarium spp. vfend deve ser administrado principalmente a pacientes com progressiva, possivelmente, ameaçam a vida, infecções. profilaxia de infecções fúngicas invasivas em alto risco de hematopoiéticas alogênico de transplante de células-tronco (hsct) destinatários.

Європейський Союз - португальська - EMA (European Medicines Agency)

xeljanz

pfizer europe ma eeig - tofacitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 e 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.